Completed PHASE2 INTERVENTIONAL 3-arm NCT00862719

Sitagliptin Umbilical Cord Blood Transplant Study

A Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies

Sponsor: Indiana University School of Medicine

Conditions Acute Lymphoblastic Leukemia Leukemia, Myelogenous, Chronic Leukemia, Myeloid, Acute Lymphoma, Non-Hodgkin Myelodysplasia

Interventions Sitagliptin

Updated 5 times since 2017 Last updated: Aug 25, 2016 Started: Mar 31, 2009 Primary completion: Nov 30, 2012 Completion: Feb 28, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Lymphoblastic Leukemia and Leukemia, Myelogenous, Chronic and is currently completed. Indiana University School of Medicine leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Indiana University School of Medicine

Data source: Indiana University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Indianapolis, United States